EUCTR2019-001656-19-ES进行中（未招募）1 期
Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKD.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. PKD diagnosis with a confirmed PKLR mutation.
- •2. Age =18 years old and <45 years for the initial 2 patients enrolled; =12–17 years for the next 2 patients; =8–11 years for the final 2 patients.
- •3. History of severe, transfusion-dependent anemia, defined as:
- •a. At least 6 RBC transfusion episodes over a prior 12-month period, or at least 3 RBC transfusion episodes per year over 2 prior years (in the absence of precipitating events such as infection or surgery) and
- •b. Hb levels <9.5 g/dL in the previous 12 months despite prior splenectomy.
- •4. Adequate cardiac, pulmonary, renal and hepatic function, as detailed in relevant exclusion criteria.
- •5. Availability of detailed medical records, including transfusion requirements, for at least the prior 2 years.
- •6. Willing and able to read and correctly understand the patient information sheet and provide consent (or informed assent for minors) regarding study participation.
- •7. Negative serum pregnancy test for female patients of childbearing potential.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 4
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Presence of other known causes of hemolysis (in addition to PKD). Patients with concurrent G6PD deficiency diagnosed during pre-study evaluation may be considered for eligibility if in the opinion of the Investigator, the hemolytic anemia is the result of PKD and the G6PD deficiency is considered an incidental finding.
- •2. A venous thromboembolic event (VTE; i.e., pulmonary embolism or deep vein thrombosis) or arteriothromboembolic event (ATE; including unstable angina, myocardial infarction, stroke or transient ischemic attack) during the prior 12 months.
- •3. Any evidence of severe iron overload that, per Investigator discretion, warrants exclusion.
- •4. Evidence of bridging fibrosis, cirrhosis or active hepatitis on liver biopsy. Liver biopsy is required when liver iron concentration (LIC) is =15 mg/g on T2* magnetic resonance imaging (MRI) of liver. If a liver biopsy has been performed less than 6 months prior to enrollment, it does not need to be repeated.
- •5. Significant medical conditions including documented HIV infection, active viral hepatitis, poorly-controlled hypertension, pulmonary hypertension, cardiac arrhythmia or congestive heart failure; or ATEs (including stroke or myocardial infarction) within the 6 prior months.
- •6. Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or another carcinoma in situ. Patients with previously resected solid organ malignancies or definitively treated hematologic malignancies may be eligible if there has been no evidence of active malignancy during the prior 3 years.
- •7. Uncontrolled seizure disorder.
- •8. Cardiac T2*<10 ms by magnetic resonance imaging (MRI) or left ventricular ejection fraction (LVEF) <45% by echocardiogram or multiple gated acquisition scan (MUGA).
- •9. Hepatic dysfunction as defined by:
- •ALT or AST >2.5× the ULN
- •10. Renal dysfunction defined as serum creatinine >ULN. Patients with creatinine above ULN may be eligible pending documentation of a glomerular filtration rate (GFR) =60 mL/min/1.73m2 as calculated by Modification of Diet in Renal Disease equation, the revised Schwartz formula (for patients under 18 years old), or 24-hour urine collection.
- •11. Pulmonary dysfunction as defined by either:
- •Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection) or
- •Oxygen saturation (by pulse oximetry) <90%.
- •12. Any medical or other contraindication for both leukapheresis and BM harvest procedure as determined by the treating Investigator.
- •13. Any medical or psychiatric condition that in the opinion of the Investigator renders the subject unfit for trial participation or at higher than acceptable risk for participation.
- •14. Poor functional status, evidenced by Karnofsky Index <70 in adults or Lansky <70 in children.
- •15. Participation in another clinical trial with an investigational drug within 14 days before the informed consent signature. Participation in observational studies is allowed.
- •16. Pregnant women or women with a positive serum pregnancy test at screening or breast feeding or planning to become pregnant within the next 24 months. Women not willing to use highly effective contraceptive methods during the complet
研究者
相似试验
招募中
不适用
Targeting Pyruvate kinase as a therapeUtic option in rare aneMiA - PUMA-Studyanemiared blood cell disease1003815810005330NL-OMON51728niversitair Medisch Centrum Utrecht115
已完成
1 期
Gene Therapy for Pyruvate Kinase Deficiency (PKD)Pyruvate Kinase DeficiencyNCT04105166Rocket Pharmaceuticals Inc.4
已完成
不适用
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)Pyruvate Kinase DeficiencyNCT03866590CENTOGENE GmbH Rostock75
已完成
不适用
Pyruvate Kinase Deficiency Natural History StudyCongenital Non-Spherocytic Hemolytic AnemiaPyruvate Kinase DeficiencyNCT02053480Boston Children's Hospital254
进行中（未招募）
不适用
Pyruvate Kinase Deficiency Global Longitudinal RegistryPyruvate Kinase DeficiencyNCT03481738Agios Pharmaceuticals, Inc.500